In the past several years, the united kingdom has witnessed a revolution in clinical pounds‑loss therapies — with the introduction of semaglutide (Wegovy®) for the expanding recognition of tirzepatide (Mounjaro®). Now, Yet another identify is drawing consideration in both clinical and public well